These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37442659)

  • 81. New Indication for Weight Loss Drug Semaglutide.
    Aschenbrenner DS
    Am J Nurs; 2023 Jun; 123(6):19. PubMed ID: 37233137
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 83. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
    Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
    Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
    Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
    Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.
    Gunning K
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1077-1079. PubMed ID: 32857647
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials.
    Verma S; David JP; Leiter LA; Michelsen MM; Rasmussen S; Bhatt DL
    Diabetes Obes Metab; 2023 Aug; 25(8):2388-2392. PubMed ID: 37016488
    [No Abstract]   [Full Text] [Related]  

  • 87. Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.
    Saito S; Nakao T
    Ther Apher Dial; 2022 Feb; 26(1):242-243. PubMed ID: 33830659
    [No Abstract]   [Full Text] [Related]  

  • 88. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
    Pace E; Tingen J
    Am Fam Physician; 2017 Oct; 96(8):540-542. PubMed ID: 29094890
    [No Abstract]   [Full Text] [Related]  

  • 90. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
    Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
    BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.
    Mahapatra MK; Karuppasamy M; Sahoo BM
    Rev Endocr Metab Disord; 2022 Jun; 23(3):521-539. PubMed ID: 34993760
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.
    Singh AK; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Mar; 16(3):102436. PubMed ID: 35245858
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
    Leiter LA; Bain SC; Bhatt DL; Buse JB; Mazer CD; Pratley RE; Rasmussen S; Ripa MS; Vrazic H; Verma S
    Diabetes Obes Metab; 2020 Sep; 22(9):1690-1695. PubMed ID: 32372454
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Dulaglutide: first global approval.
    Sanford M
    Drugs; 2014 Nov; 74(17):2097-103. PubMed ID: 25367716
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
    Kim HS; Jung CH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Diabetes: Cardiovascular benefits of semaglutide.
    Lim GB
    Nat Rev Cardiol; 2016 Dec; 13(12):697. PubMed ID: 27708277
    [No Abstract]   [Full Text] [Related]  

  • 97. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
    Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
    Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Semaglutide injection for the treatment of adults with type 2 diabetes.
    Chudleigh RA; Bain SC
    Expert Rev Clin Pharmacol; 2020 Jul; 13(7):675-684. PubMed ID: 32476529
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes.
    Meyer J; Dreischmeier E; Lehmann M; Phelan J
    Ann Pharmacother; 2023 Mar; 57(3):241-250. PubMed ID: 35778801
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
    Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
    Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.